MIKROBIOTA VA YURAK SALOMATLIGI: ICHAK FLORASINING ATEROSKLEROZGA TA’SIRI
Keywords:
Mikrobiota, ateroskleroz, TMAO, qisqa zanjirli yog‘ kislotalari, immun javob, disbioz, yurak salomatligi, probiotik, prebiotik, metabolitlar.Abstract
Ateroskleroz — yurak-qon tomir kasalliklarining asosiy patogenetik mexanizmlaridan biri bo‘lib, global sog‘liqni saqlash tizimida o‘lim ko‘rsatkichlarining yuqoriligiga sabab bo‘lmoqda. So‘nggi yillarda ilmiy tadqiqotlar ichak mikrobiotasi yurak salomatligida muhim rol o‘ynashini ko‘rsatmoqda. Ichakdagi trillionlab mikroorganizmlar nafaqat ovqat hazm qilishda, balki metabolizm, immun javob va qon tomirlarning funksional holatini tartibga solishda ham ishtirok etadi. Ayniqsa, mikrobiota tomonidan ishlab chiqariladigan metabolitlar — trimetilamin-N-oksid (TMAO), qisqa zanjirli yog‘ kislotalari (QZYK) va safro kislotalari ateroskleroz rivojlanishida bevosita ishtirok etadi. TMAO darajasining yuqoriligi ateroskleroz va yurak xuruji xavfini oshirishi aniqlangan, QZYK esa yallig‘lanishni kamaytirib, yurakni himoya qiladi. Ushbu maqolada mikrobiota va ateroskleroz o‘rtasidagi asosiy bog‘liqliklar, metabolik mexanizmlar, klinik tadqiqotlar natijalari hamda davolash strategiyalari keng yoritiladi. Shuningdek, parhez, probiotiklar, prebiotiklar va mikrobiota transplantatsiyasi orqali yurak salomatligini yaxshilash imkoniyatlari muhokama qilinadi. Natijada, mikrobiota yurak-qon tomir kasalliklarida yangi diagnostik va terapevtik yondashuvlar uchun istiqbolli yo‘nalish sifatida qaralmoqda.
References
1. Tang W. H. W. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. New England Journal of Medicine, 2013.
2. Karlsson F. H. et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nature Communications, 2012.
3. Cani P. D. et al. Gut microbiota at the intersection of diet and health. Science, 2019.
4. Wang Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature, 2011.
5. Kasahara K., Rey F. E. The emerging role of gut microbiota in cardiovascular disease. Journal of Cardiology, 2019.
6. Jie Z. et al. The gut microbiome in atherosclerotic cardiovascular disease. Nature Communications, 2017.
7. Koeth R. A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine, 2013.
8. Marques F. Z. et al. The gut microbiome and hypertension. Current Opinion in Nephrology and Hypertension, 2018.
9. Li J. et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome, 2017.
10. Brown J. M., Hazen S. L. The gut microbial endocrine organ: TMAO as a modulator of cardiovascular risk. Journal of Clinical Investigation, 2014.
11. Kobyliak N. et al. Probiotics and cardiovascular diseases. BioMed Research International, 2016.
12. Wu G. D. et al. Linking long-term dietary patterns with gut microbial enterotypes. Science, 2011.
13. Zhernakova A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science, 2016.
14. Kasahara K. et al. Interactions between the gut microbiome and host lipid metabolism. Nature Reviews Cardiology, 2018.
